Clinical Trials Logo

Thoracic Aortic Aneurysms clinical trials

View clinical trials related to Thoracic Aortic Aneurysms.

Filter by:
  • None
  • Page 1

NCT ID: NCT03142074 Recruiting - Clinical trials for Thoracic Aortic Aneurysms

Biomechanical and Microstructural Properties of Ascending Aortic Aneurysms

Start date: January 2017
Phase:
Study type: Observational [Patient Registry]

An aortic aneurysm (thoracic or abdominal) is a permanent dilatation of the aorta caused by weakening in the arterial wall. The feared complication is aortic rupture or dissection, leading to potentially lethal aortic bleeding and associated with mortality rates up to 95%. The current diagnosis criteria do not suffice, therefore the goal of this study is the development of an improved biomechanics-based and microstructural-based diagnostic tool.

NCT ID: NCT01839695 Completed - Clinical trials for Thoracic Aortic Aneurysms

Safety and Efficacy of Valiant Mona LSA Stent Graft System

Start date: April 2013
Phase: N/A
Study type: Interventional

The Valiant Mona LSA thoracic stent graft system is for the endovascular repair of aneurysms of the descending thoracic aorta (DTA) in patients who require coverage of the left subclavian artery (LSA).The study is intended to assess safety and performance of the device acutely and at 30 days.

NCT ID: NCT00805948 Terminated - Clinical trials for Thoracic Aortic Aneurysms

Post-Approval Clinical Study of the Talent Thoracic Stent Graft to Treat Thoracic Aortic Aneurysms (THRIVE)

THRIVE
Start date: April 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and effectiveness of the Talent Thoracic Stent Graft System for treatment of descending thoracic aneurysms (DTA)following U.S. market approval.

NCT ID: NCT00604799 Completed - Clinical trials for Thoracic Aortic Aneurysms

VALOR: The Talent Thoracic Stent Graft System Clinical Study

VALOR
Start date: July 2003
Phase: Phase 2/Phase 3
Study type: Interventional

A Descending Thoracic Aneurysm is a bulge in the aorta. The aorta is a large blood vessel that carries blood away from your heart to organs in the rest of your body. Your aneurysm is caused by a weakening in the artery wall. If left untreated, this bulge may continue to grow larger and may ultimately rupture (break open) or extend in size to seriously affect other major arteries in the area. In this Research Study a device will be placed inside your aorta to block the weakened part of the artery wall from the circulatory system. Information will be collected on the performance for the device for 5 years.

NCT ID: NCT00597870 Completed - Clinical trials for Thoracic Aortic Dissection

Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions

Start date: May 2002
Phase: N/A
Study type: Interventional

The primary objective of this trial is to determine whether the Talent Thoracic Stent Graft, an investigational device, is a safe and effective method of treating thoracic aortic aneurysms (abnormal ballooning of the vessel wall) and other thoracic lesions (dissections, transections, pseudoaneurysms, penetrating ulcers, etc.). The endovascular method is a substitute for the major operation that is performed to treat the lesions.

NCT ID: NCT00583817 Enrolling by invitation - Aortic Dissection Clinical Trials

Endovascular Treatment of Thoracic Aortic Disease

EVOLVE Aorta
Start date: October 25, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the role endovascular therapy to treat aortic disease involving the ascending aorta, the aortic arch, and the visceral segment of the aorta (or thoracoabdominal aorta)

NCT ID: NCT00435942 Completed - Clinical trials for Thoracic Aortic Aneurysms

Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

Start date: January 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the Relay thoracic stent-graft system to treat thoracic aortic aneurysms. Efficacy will be evaluated by the device-related adverse event rate of endovascular repair (via Relay Thoracic Stent-Graft) through 1-year. Safety will be evaluated by comparing major adverse events through 1-year in subjects treated with the Relay Thoracic Stent-Graft to those who underwent surgical repair. Long term follow-up is conducted through 5 years.